MRC / AstraZeneca Small Molecule HTS
Supports high-throughput small molecule discovery for faster medicine development and health impact.
The MRC/AstraZeneca Small Molecule High-Throughput Screening (HTS) programme is a joint initiative between the Medical Research Council and AstraZeneca that provides academic researchers with access to AstraZeneca's compound libraries, screening facilities, and scientific expertise for small-molecule drug discovery. The programme funds up to four projects per annual round from a total pool of £1,0…
Small molecule high-throughput screening of novel biological targets using AstraZeneca compound libraries and facilities, co-funded by MRC and AstraZeneca for up to four projects per year.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline